close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Virpax Pharmaceuticals, Inc. - Common Stock (NQ:VRPX)

0.6695 UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Virpax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Reports 2022 Third Quarter Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dr. Jeffrey Gudin, Chief Medical Officer of Virpax Pharmaceuticals, to Present Poster at World Congress of World Institute of Pain
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pursues OTC Medical Device Pathway for AnQlar™
From Virpax Pharmaceuticals
Via Business Wire
News headline image
Virpax Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis
From Virpax Pharmaceuticals
Via Business Wire
News headline image
Virpax Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Reports 2022 First Quarter Results and Recent Developments
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Enters Into CRADA With The U.S. Army Institute of Surgical Research
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Successfully Completes Initial Preclinical Studies for VRP324
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Reports 2021 Year-End Results
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Completes All FDA-Required Pre-Clinical Studies for Epoladerm™
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
News headline image
Nanomerics Receives Further Upfront Payment for Anti-Viral Spray AnQlar(TM)
LONDON, UK / ACCESSWIRE / March 22, 2022 / Nanomerics Ltd., a private speciality pharmaceutical company, today announced the receipt of a further milestone payment on agreeing the expansion of its... 
From Nanomerics Ltd
Via AccessWire
News headline image
Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
News Outlets Highlight Virpax Pharmaceuticals and Its Potential Solutions for the Opioid Crisis and COVID-19
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Reports Favorable Preclinical Safety Data for Envelta™  for the Treatment of Acute and Chronic Pain
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm™ for Chronic Pain Associated with Osteoarthritis of the Knee
From Altasciences and Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax® Successfully Completes Preclinical Dermal Safety Studies for Epoladerm™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax® Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
From Virpax® Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Recaps Milestones and Highlights Product Portfolio
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm™ for Pain Associated with Osteoarthritis of the Knee
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Reports 2021 Third Quarter Results and Recent Developments
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Advances Envelta™ Development with NCATS Under CRADA Agreement
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax Signs Agreement with Sinclair Research to Initiate Investigational New Drug (IND)-Enabling Studies for AnQlar™
From Virpax Pharmaceuticals Inc.
Via Business Wire
News headline image
Virpax to Present at the NobleCon Online Pain Management Investor Forum on Channelchek.com on October 7, 2021
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children
From Virpax Pharmaceuticals, Inc.
Via Business Wire
News headline image
Virpax® Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock
From Virpax Pharmaceuticals Inc.
Via Business Wire
News headline image
Virpax® Pharmaceuticals Announces Pricing of $40 Million Public Offering of Common Stock
From Virpax Pharmaceuticals Inc.
Via Business Wire
News headline image
Virpax Pharmaceuticals Announces Poster Presentation for Envelta™ at PAINWeek 2021
From Virpax Pharmaceuticals
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today